Recruitment, response rates and characteristics of 5511 people enrolled in a prospective clinical cohort study: head and neck 5000


*School of Oral and Dental Sciences, National Institute for Health Research (NIHR) Biomedical Research Unit in Nutrition, Diet and Lifestyle, University Hospitals Bristol NHS Foundation Trust; †School of Oral and Dental Sciences, University of Bristol; ‡Surgical Research Team, University Hospitals Bristol NHS Foundation Trust; §School of Social and Community Medicine, University of Bristol, Bristol, UK; ¶National Cancer Research Institute Consumer Liaison Group (NCRI CLG), Independent Cancer Patients Voice (ICPV), London, UK; **MRC Integrative Epidemiology Unit and Avon Longitudinal Study of Parents and Children, School of Social and Community Medicine, School of Clinical Sciences, University of Bristol, Bristol, ††Cochrane Oral Health Group, School of Dentistry, University of Manchester, Manchester, §§Royal Marsden Hospital and the Institute for Cancer Research, London, ¶¶Leeds Institute for Cancer and Pathology, University of Leeds, Leeds, ***Evidence-Based Practice Research Centre (EPRC), Faculty of Health and Social Care, Edge Hill University, Ormskirk, Lancashire, UK

Accepted for publication 25 September 2015

Dear Editor,

Head and neck cancer is an important cause of ill health with rapidly changing aetiology and approaches to treatment.1,2 Survival appears to have improved, but the reasons for this are unclear.3 There is no large population-based comprehensive longitudinal biomedical resource of people with head and neck cancer. Several registries exist, such as the US National Cancer Institute surveillance epidemiology and end results programme, but these lack individual consent and biological samples.4 Large retrospective aetiological case-control studies with consent, clinical and socio-demographic information and biological samples, such as the International Head and Neck Cancer Epidemiology Consortium, have limited follow-up data, focus on past rather than current exposures and recruited people at different stages of treatment.5 Existing prospective studies have fewer than 1000 participants and are often based on follow-up of randomised trials (a potentially unrepresentative group).6

The importance of adequately powered, population-based, comprehensive, longitudinal biomedical resources in healthy populations is accepted. The value of similar biomedical resources for clinical conditions is increasingly appreciated. We report here on recruitment, response rates and characteristics of 5511 people enrolled in a prospective clinical cohort study: head and neck 5000.7

Methods

Ethical considerations

The study was approved by the National Research Ethics Committee (South West Frenchay Ethics Committee, reference 10/H0107/57, 5th November 2010) and approved by the research and development departments for participating NHS Trusts.

Recruitment to the study

We have described the study methods in detail previously.7 Briefly, all people with a new diagnosis of head and neck cancer were eligible. People were recruited before their treatment started, unless their treatment was their diagnostic procedure. Participants offered palliative support were recruited as soon after diagnosis as possible. A research nurse obtained a wide-ranging consent. The teams kept logs of the number of eligible people who were approached and the reason they were not recruited.

Baseline data and sample collection

The research nurse gave participants three questionnaires. The first enquired about social and economic circumstances, overall health and lifestyle behaviours. The second enquired about physical and psychological health, well-being and quality of life. The third enquired about past sexual behaviours.7 The nurse abstracted information from the hospital medical records about diagnosis, treatment and
comorbidity onto a data capture form and asked participants to provide a blood sample and a saliva sample. The nurse posted the samples to the study laboratory. We asked local pathologists to send paraffin embedded tumour blocks along with an anonymised copy of the participant’s histopathology report.7

**Study follow-up**

We have not collected any further biological samples. We sent out follow-up questionnaires at 4 and 12 months after the person joined the study. We added questions about fear of recurrence in the 4- and 12-month questionnaires. A separate questionnaire asking about late radio-toxicity was sent to people at 12 months who had a course of radiotherapy as part of their initial treatment plan. The research nurses abstracted updated clinical information from the hospital medical records at 4 and 12 months. We have flagged participants with the UK Health and Social Care Information Centre to obtain data on date and cause of death.

**Statistical analysis**

Age was calculated from the date on the consent form and the date of birth on the data capture form. Gender, diagnosis and stage were recorded on the data capture form. We coded diagnosis using the International Classification of Diseases (ICD) version 10.8 We derived the clinical staging of the tumour from T (characteristics of the tumour site), N (degree of lymph node involvement) and M (the absence or presence of metastases) based on the American Head and Neck Society TNM staging of head and neck cancer.9 We present numbers and percentages overall and for different diagnostic groups.

**Results**

**Recruitment**

We started recruiting in April 2011 and closed to recruitment at the end of December 2014. We opened the study in a few centres to ensure the protocol was running smoothly before rolling it out elsewhere. The study was open in 78 UK centres (two centres did not enrol any participants). We enrolled 5511 people into the study.

**Baseline response rates**

At baseline, we have received 5474 (99%) data capture forms, 4099 (74%) health and lifestyle questionnaires, 4115 (75%) quality of life questionnaires and 3470 (63%) sexual history questionnaires. We have obtained 4986 saliva samples (90%), 4676 blood samples (85%) and 2301 tissue samples (42%). Twenty-three people withdrew from completing baseline questionnaires.

**Follow-up response rates**

To date, 827 people enrolled by 24 July 2015 have died and 74 have withdrawn from the study. We have 4-month data capture forms for 5232 (95%) and 4-month questionnaires from 3357 (63%) participants and 12-month data capture forms for 3906 (86%) and 12-month questionnaires from 2353 (57%) participants. These follow-up response percentages are the number received against the number for which we are expecting forms, that is those who provided baseline data and remain in the study. They do not include participants who have not yet reached, or died before, the relevant 12-month window.

**Recruitment and response rate by centres**

Centres varied in size and joined the study at different times. The mean number of people recruited per centre was 40 (range from 0 to >300). Similarly, there were large variations in response rates by centres. Percentage recruitment to the study varied from less than 20% to greater than 90% of those eligible, response rate to the health and lifestyle questionnaire varied from less than 30% to greater than 90% and the percentage of participants providing a blood sample varied from less than 50% to greater than 90%. These differences are shown in Fig. 1.

---

Fig. 1. Variation in recruitment and response rates by centres in head and neck 5000. These box plots show the median and interquartile ranges of recruitment and response rate across the participating study centres with outliers indicated by whiskers. The percentage consented refers to the number of eligible people who consented to join the study whereas the other response rates refer to the percentage of those recruited who returned a questionnaire.
Characteristics of participants

The percentage of people enrolled in the study was 5511 from 11,158 people who were identified as potentially eligible (49%). The mean age of the people recruited was 61 years, and the range was 18–96 years. The percentage of female participants was 27%. The most common cancers were oropharyngeal (37%), oral (26%) and laryngeal (21%). The number and percentage of people with different diagnoses and stage of disease is summarised in Table 1. The number of people with complete data (defined as valid diagnosis, stage, blood sample and baseline health and lifestyle questionnaire) was 3336 of the 5511 (61%). The number of people with complete data to date is shown in Fig. 2.

Discussion

We have successfully recruited 5511 people with head and neck cancer from across the UK. We recruited people before treatment started and obtained wide-ranging consent, clinical information, self-reported socio-demographic, lifestyle and quality of life data and biological samples.

We took time to build a clinical consensus and opened to recruitment gradually. This delayed recruitment but meant we encountered few local problems. One clinician initially refused to allow people under his care to complete the sexual behaviour questionnaire. The response rates to this questionnaire are slightly lower, but we have had no complaints about these questions.

We recruited fewer people with salivary, thyroid and laryngeal cancers than we expected. The lower number of people with salivary tumours may reflect the coding of some minor salivary gland cancers as oral cancer. The lower number of people with thyroid cancers reflects the fact that many are not treated by the head and neck multidisciplinary team. The lower number of laryngeal cancers may reflect the case mix in the study centres.

Table 1. Disease category and stage of disease in people recruited to head and neck 5000

<table>
<thead>
<tr>
<th>Category</th>
<th>Diagnosis</th>
<th>Grouped staging</th>
<th>I</th>
<th>II</th>
<th>III</th>
<th>IV</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Upper aerodigestive tract</td>
<td>Oropharynx</td>
<td></td>
<td>101</td>
<td>189</td>
<td>274</td>
<td>1317</td>
<td>1881</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>5.4%</td>
<td>10.1%</td>
<td>14.6%</td>
<td>70.0%</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Oral cavity</td>
<td></td>
<td>427</td>
<td>300</td>
<td>101</td>
<td>467</td>
<td>1295</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>33.0%</td>
<td>23.2%</td>
<td>7.8%</td>
<td>36.1%</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Larynx</td>
<td></td>
<td>435</td>
<td>276</td>
<td>174</td>
<td>186</td>
<td>1071</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>40.6%</td>
<td>25.8%</td>
<td>16.3%</td>
<td>17.4%</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Hypopharynx</td>
<td></td>
<td>10</td>
<td>33</td>
<td>35</td>
<td>150</td>
<td>228</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>4.4%</td>
<td>14.5%</td>
<td>15.4%</td>
<td>65.8%</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Nasopharynx</td>
<td></td>
<td>11</td>
<td>32</td>
<td>43</td>
<td>42</td>
<td>128</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>8.6%</td>
<td>25.0%</td>
<td>33.6%</td>
<td>32.8%</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Sinuses</td>
<td></td>
<td>3</td>
<td>2</td>
<td>7</td>
<td>43</td>
<td>55</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>5.5%</td>
<td>3.6%</td>
<td>12.7%</td>
<td>78.2%</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Nasal cavity</td>
<td></td>
<td>12</td>
<td>15</td>
<td>6</td>
<td>16</td>
<td>49</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>24.5%</td>
<td>30.6%</td>
<td>12.2%</td>
<td>32.7%</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Thyroid</td>
<td></td>
<td>119</td>
<td>31</td>
<td>73</td>
<td>18</td>
<td>241</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>49.4%</td>
<td>12.9%</td>
<td>30.1%</td>
<td>7.5%</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Salivary glands</td>
<td></td>
<td>33</td>
<td>21</td>
<td>22</td>
<td>55</td>
<td>131</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>25.2%</td>
<td>16.0%</td>
<td>16.8%</td>
<td>42.0%</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Total</td>
<td></td>
<td>1151</td>
<td>899</td>
<td>735</td>
<td>2294</td>
<td>5079</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>22.7%</td>
<td>17.7%</td>
<td>14.5%</td>
<td>45.2%</td>
<td></td>
</tr>
</tbody>
</table>

The categories comprised the following ICD codes:

Oropharynx = C01, C05 and C09 (including all subcategories) and C10.0 2, C10.3, C10.8 and C10.9.

Oral cavity = C00, C02, C03, C04, C05 and C06 (including all subcategories except C06.9).

Larynx = C10.1, C32 (including all subcategories).

Hypopharynx = C12 and C13 (including all subcategories).

Nasopharynx = C11 (including all subcategories).

Sinuses = C31 (including all subcategories).

Nasal cavity = C30 (including all subcategories).

Thyroid = C73.

Salivary glands = C06.9, C07 and C08 (including all subcategories).
Overall, around 49% of eligible people consented to join the study and of these 61% have provided us with complete baseline data. Therefore, we have data on around 30% of people eligible to join the study. Our baseline response rates were lower than we anticipated. There are several reasons for this. We tried to obtain consent and collect data from people in the short period between diagnosis and treatment. Clinics were busy with limited space or time to see people. We faced practical issues with people moving between centres for treatment or not being discussed at the multidisciplinary team meetings. There were also times when research nurses were not available.

Some of the missing data may be unrelated to care or outcome, for example, where a research nurse was unavailable. However, much of the data will not be missing at random and could result in bias. We may be able reduce the impact of bias in recruitment and response to follow-up by improving the completeness of our clinical data and exploring the clinical characteristics of those who did not consent to join the study by linking to national audit data.\(^\text{10}\)

Our ability to study the impact of centralisation (which was a primary aim of our study) is limited by the low recruitment rate, the fact that centres, although varied in size, were self-selected and that not all centres contributing to a multidisciplinary team recruited people to the study.

We have shown it is possible to recruit a large DNA-backed clinical cohort in people with head and neck cancer in the UK. This cohort is a comprehensive resource, and we welcome collaboration.

**Acknowledgements**

We would like to thank the people with head and neck cancer who took part in this study. We would also like to thank the...
research, laboratory and clinical staff who supported this study. This publication presents independent research funded by the National Institute for Health Research (NIHR) under its Programme Grants for Applied Research scheme (RP-PG-0707-10034). The views expressed in this publication are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health. We would specifically like to thank members of the Bristol co-ordinating team and the laboratory team: Mrs Christine Wood (Research Coordinator), Mrs Vikki Yip (Chief Technician) and Dr Martin Persson (previous project manager). We would also like to acknowledge the principal investigators at Head and Neck 5000 study sites. These include the following members: Professor Simon Rogers (Aintree), Mr JK Thiruchelvam (Barnet & Chase Farm), Dr Maged Abdelkader (Basildon), Mr Shahram Anari (Birmingham Heartlands), Professor Hisham Mehanna (Birmingham QEH), Dr Tom Sheehan (Boston), Dr Karen Dyker and Mr James McCaul (Bradford), Dr Richard Benson (Cambridge University Hospitals NHS Trust), Dr Simon Stewart (Charing Cross), Mr Charles Hall (Cheltenham General Hospital), Dr Jim Lester (Chesterfield Royal Hospital), Mr Jarrod Homer (Christie), Dr Abdul Hamid and Dr Alan Lamont (Colchester), Dr Lydia Fresco and Professor Hisham Mehanna (Coventry), Mr Shane Lester (Darlington Memorial Hospital), Dr Geoffrey Cogill and Dr Amy Roy (Derriford Hospital Plymouth), Dr Bernie Foran (Doncaster Royal Infirmary), Mr Brian Bisase (East Grinstead), Mr Alistair Balfour (East Kent (Kent & Canterbury)), Mr Andrew Evans (Fife), Dr Simon Gollins (Glan Clwyd Hospital, Rhyl), Dr David Conway (Glasgow), Mr Charles Hall (Gloucestershire Royal Hospital), Dr Sinnappa P Gunasekaran (Grimsby), Mrs Laura Lees and Ms Rachel Lowe (Hereford (Wye Valley NHS Trust)), Mr James England (Hull & East Yorks), Dr Christopher Scrase (Ipswich), Mr Richard Wight (James Cook, Middlesbrough, South Tees Hospitals NHS Foundation Trust), Dr Mehmet Sen (Leeds), Ms Margret Doyle (Leighton), Dr Russell Moule (Lister Hospital (East and North Hertfordshire NHS Trust)), Dr Kate Goodchild (Luton), Dr Nick Rowell (Maidstone), Ms Dawn Beaumont-Jewell and Dr HW Loo (Mid Essex Hospital), Dr Kate Goodchild (Mount Vernon), Dr Petra Jankowska (Musch Grove Park, Taunton), Mr Vinidh Paleri (Newcastle), Dr Richard Casasola (Norwich), Dr Tom Roques (Norfolk and Norwich), Mr Paul Tierney (North Bristol), Dr David Hwang (North Devon District Hospital), Dr P Dyson (North Cumbria), Dr Gerard Andrade (Northampton), Mr Taran Tatla (Northwick Park), Dr Judith Christian (Nottingham University Hospitals NHS Trust), Mr Stuart Winter (Oxford), Mr Andrew Baldwin (PENNINE), Dr Joe Davies and Dr Emma King (Poole), Ms Debi Barnes, Mr Costas Repanos and Dr Jae Kim (Portsmouth), Mr Stuart Richards (Rotherham), Dr Nicola Dallas (Royal Berkshire Hospital), Dr David Hwang (Royal Devon & Exeter Hospital), Dr Sandeep Berry, Dr Naomi Cole and Dr Laura Moss (Royal Glamorgan), Dr Nachi Palaniappan and Dr Mererid Evans (Royal Gwent Hospital), Mr Jarrod Homer (Royal Manchester), Professor Christopher Nutting (Royal Marsden London), Professor Christopher Nutting (Royal Marsden Sutton), Dr Muthu Siva (Royal Preston Hospital Lancashire Teaching Hospitals NHS Foundation Trust), Mr Churun Hari (Royal Shrewsbury and Telford Hospital NHS Trust), Dr Katie Wood (Royal Surrey County Hospital NHS Foundation Trust), Dr Richard Simcock (Royal Sussex), Mr John Waldron (Royal United Hospitals Bath), Mr Nicholas Hyde (St Georges), Dr Sinnappa P Gunasekaran and Dr Abdul Hamid (Scunthorpe General Hospital), Dr Bernie Foran (Sheffield), Dr Imtiaz Ahmed (Southend), Dr Daljit Gahir (Stoke City General), Mr James O’Hara (Sunderland Royal Hospital), Dr Ruth Carr (Torbay), Dr Martin Forster (University College London Hospital), Dr Tom Sheehan (United Lincolnshire Hospital), Professor Steve Thomas (UH Bristol), Dr Mererid Evans (UH Wales), Mrs Lynda Wagstaff (Walsall), Dr Joseph Mano and Dr Caroline Brammer (Wolverhampton), Mrs Jayne Tyler (Worcestershire) and Mr Andrew Coatesworth (York).

Keypoints

- Head and neck cancer is an important cause of ill health with rapidly changing aetiology. 
- Survival appears to have improved but the reasons for this are unclear. 
- Adequately powered, longitudinal studies in people with head and neck cancer are required. 
- We recruited 5511 people with head and neck cancer to a large DNA-backed clinical cohort. 
- Multicentre clinical cohort studies in head and neck cancer are feasible in the UK.

Conflict of interest

None declared.

References


4 The US National Cancer Institute surveillance epidemiology and end results programme. URL http://seer.cancer.gov/data/ [accessed on 22 October 2015]

5 The International Head and Neck Cancer Epidemiology Consortium. URL http://www.inhance.utah.edu/ [accessed on 22 October 2015]


10 The UK National Head and Neck Audit. URL http://www.hscic.gov.uk/headandneck [accessed on 22 October 2015]